Corindus to Feature the CorPath® GRX System at the Transcatheter Cardiovascular Therapeutics 2018 Conference
Published: Sep 14, 2018
Breakfast symposium and immersive booth activities highlight capabilities of vascular robotic technology and importance of remote access to care
WALTHAM, Mass.--(BUSINESS WIRE)-- Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, will feature its CorPath® GRX System at the Transcatheter Cardiovascular Therapeutics (TCT) 2018 Conference, September 21 – 25, in San Diego, CA. Corindus' CorPath GRX is the first FDA-cleared medical device for robotic-assisted vascular interventions. The company will showcase its revolutionary technology throughout the conference through live cases and presentations, during a Corindus-sponsored breakfast symposium, and at Booth 421.
On Sunday, September 23, 2018 from 6:30 a.m. – 8:00 a.m., Corindus' Cardiovascular Chief Medical Officer, Dr. J. Aaron Grantham of St. Luke's Hospital of Kansas City, will chair the breakfast symposium, "New Frontiers in Robotic Interventions: Current and Future Technology." The agenda will include the following topics:
- "New Clinical Evidence in Robotic Interventions" presented by Lawrence Ang, M.D.
- "Robotics for Complex PCI: A Case Series" presented by Manish A. Parikh, M.D.
- "The 1st Remote PCI from 100 Miles Away" presented by Ryan Madder, M.D.
- "Building the Next Generation Robot" presented by Mitchell Krucoff, M.D.
Space for the breakfast symposium is limited; please register at www.tctconference.com/satelliteprograms.
"I am pleased to chair this educational program with an esteemed group of interventionalists to highlight the current and future capabilities of vascular robotics. There has been tremendous progress made in the development of our robotic platform, including procedural automation and remote technology, which we believe will have the power to change the treatment paradigm and increase patient access to care," said J. Aaron Grantham, M.D., Cardiovascular Chief Medical Officer of Corindus.
The CorPath GRX System will be on display at Corindus' Booth 421. Attendees will have the opportunity to be among the first to experience future procedural automation techniques and compete with their peers in a wiring challenge. To schedule a hands-on demonstration of vascular robotics with an advanced simulator, please visit www.corindus.com/TCT2018.
Transcatheter Cardiovascular Therapeutics (TCT) is the world’s largest and most important educational meeting specializing in interventional cardiovascular medicine. For 30 years, TCT has been the center of cutting-edge educational content, showcasing the latest advances in current therapies and clinical research. This symposium is designed for interventional cardiologists, radiologists, clinical cardiologists, scientists, vascular medicine specialists, cardiac and vascular surgeons, nurse practitioners, cath lab technicians, and other healthcare professionals with a special interest in the field of interventional and vascular medicine.
About Corindus Vascular Robotics, Inc.
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath® System is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary and vascular procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. CorPath GRX is the second generation robotic-assisted technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. For additional information, visit www.corindus.com, and follow @CorindusInc.
Forward Looking Statements
Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Corindus’ control.
Examples of such statements include statements regarding or such as:
- the tremendous progress made in the continued development of robotic technology, including telerobotics, which we believe will have the power to change the treatment paradigm and increase patient access to care.
Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled "Risk Factors" in the Company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, including, but not limited to the following: our ability to expand our technology platform and achieve the advances necessary for telestenting and remote procedures, including in humans; our ability to expand our technology platform for use in other segments of the vascular intervention market, including neurointerventional and other more complex cardiac interventions; obtaining necessary regulatory approvals for the use on humans and marketing of our products in the United States and in other countries; risks associated with market acceptance; our ability to enforce our intellectual property rights; our need for additional funds to support our operations; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; and potential safety and regulatory issues that could slow or suspend our sales. Forward looking statements speak only as of the date they are made. Corindus undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date. More information is available on Corindus' website at http://www.corindus.com.
Source: Corindus Vascular Robotics, Inc.